A Science and Technology Blog
Developed by Washington University School of Medicine in St. Louis, the vaccine has been licensed to Bharat Biotech to carry out human clinical trials, manufacture the vaccine and distribute them…
By following the U.K. model of vaccinating people based on age bands rather than focussing on comorbidities, millions of people would become eligible to receive the vaccine and be fully…
According to details posted on the clinical trial registry, the company had planned to “continue the phase-3 trial until 130 study participants developed PCR-confirmed symptomatic COVID-19 disease during follow-up beginning…
While it is unclear if pre-existing antibodies to adenovirus vector will affect vaccine efficacy, it is possible that repeated vaccination using adenovirus-based vaccine either as a booster or as annual vaccination, if the need arises, will result in reduced efficacy due to vector immunity.
Even as recently as March 6, March 4, March 3, March 2 and March 1 the Health Ministry mischievously implicated Kerala for the surge in cases when it included Kerala…
The vaccine efficacy was measured based on symptomatic COVID-19 disease — mild, moderate or severe — two weeks after the second dose. The interim analysis undertaken at the first endpoint…
The results have been posted on medRxiv preprint server. Preprints are yet to be peer-reviewed and published in scientific journals. Though measurements were made only till day 28 after the…
“The list of comorbidities provided by the Health Ministry is overly restrictive and complicated. Many conditions, including obesity, have been left out,” says Dr. Gagandeep Kang, Professor of Microbiology at…
